Wednesday, July 8, 2026

pharma · Prostate Cancer · Autoimmune · JANX

Janux Therapeutics

Janux Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

San Diego, USA HQ
2017 Founded
110 Employees
Public company Type
JANX · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2017
Employees
110
Programs
4
Drugs
0
Patents
2
Intelligence · Clinical Programs

Janux Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Janux Therapeutics.

Janux Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. JANX007

    Janux Therapeutics

    Prostate Cancer

    phase 1 mab active

    1 trial
  2. JANX008

    Janux Therapeutics

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial
  3. JANX011

    Janux Therapeutics

    Autoimmune

    phase 1 small molecule active

    1 trial
  4. JANX014

    Janux Therapeutics

    Prostate Cancer

    phase 1 mab active

    1 trial

Frequently asked questions

How many clinical projects does Janux Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.